Assured Pharmacy closes one of its Oregon locations
IRVINE, Calif. Assured Pharmacy announced the closing of one Oregon pharmacy location on Thursday. The pharmacy is now being consolidated into Assureds’ other location in Portland, where the company feels it will leverage its existing infrastructure, and reduce costs.
Assured is a retail company that focuses on patients who have chronic pain, as well as physicians who treat it. The goal of the company has been to seek areas with a high volume of physicians and to have an advantage in the marketplace to sell chronic pain medications, and to reach their annual revenue target of $5 million per pharmacy, another reason for closing one of two locations in the same city.
“We are exploring other potential locations in the Oregon area, as well as in other states,” Robert Delvecchio, chief executive officer of Assured Pharmacy, stated. “At this early stage in our growth, we believe we are able to cherry pick the best opportunities for our new pharmacy locations. The strength of our business model is in the financial metrics. We remain committed to growing and developing retail pharmacies in locations in which our careful due diligence indicates significant demand for our services.”
IVoice announces patent on new product for easy medicine consumption
MATAWAN, N.J. iVoice has created a new product that will organize the way that patients consume pills. According to published reports, the invention is a medicine container that has speaking instructions.
iVoice has filed a patent application with the U.S. Patent and Trademark Office under the title, “Methodology for Wirelessly Loading Speaking Medicine Containers, with an internal clock.”
The new iVoice product contains an internal clock, which starts when a patient activates the audio playback that, with recurring use, creates a message that displays how many pills the patient should have left, and if that “predetermined amount” is not in the container, a warning is displayed for the patient to contact a doctor or pharmacist. Other features include a medicine container starting table count, required consumption data and self-programming.
FTC files complaint over Cephalon’s attempt at protection of Provigil market
WASHINGTON Cephalon is facing a lawsuit filed by antitrust enforcers regarding its Narcolepsy medicine, Provigil.
Provigil is Cephalon’s best-selling drug, and according to the Wall Street Journal, the civil complaint filed by the Federal Trade Commission stated that Cephalon was illegally delaying the sale of the drug by four rivals that were slated to produce and market the generic version of the drug. The sales of Provigil are a recorded $800 million per year.
According to the Wall Street Journal report, companies including Teva Pharmaceuticals, Ranbaxy Pharmaceuticals, Barr Pharmaceuticals, and Mylan Pharmaceuticals, were given a combined $200 million to push off the genetic version of their drug from market entry until 2012.
Cephalon denies any wrongdoing. “The transactions we reached met the letter and spirit of the law in every way,” Frank Baldino, Cephalon’s chief executive, said, “and we will litigate this matter, and we will prevail.”